Ebola haemorrhagic fever, The Lancet, vol.377, issue.9768, pp.849-62, 2011. ,
DOI : 10.1016/S0140-6736(10)60667-8
Discussions and decisions of the 2012???2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012???June 2013, Archives of Virology, vol.155, issue.4, pp.821-851, 2012. ,
DOI : 10.1007/s00705-013-1846-9
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations, Archives of Virology, vol.67, issue.12, pp.2083-103, 2010. ,
DOI : 10.1007/s00705-010-0814-x
Clinical features and pathobiology of Ebolavirus infection, Journal of Autoimmunity, vol.55, pp.1-9, 2014. ,
DOI : 10.1016/j.jaut.2014.09.001
Emerging Targets and Novel Approaches to Ebola Virus Prophylaxis and Treatment, BioDrugs, vol.76, issue.12, pp.565-83, 2013. ,
DOI : 10.1007/s40259-013-0046-1
Phylogenetic Analysis of Guinea 2014 EBOV Ebolavirus Outbreak, PLoS Currents, vol.6, 2014. ,
DOI : 10.1371/currents.outbreaks.84eefe5ce43ec9dc0bf0670f7b8b417d
Ebola virus disease, BMJ, vol.349, issue.dec10 28, p.7348, 2014. ,
DOI : 10.1136/bmj.g7348
Risk Factors Associated with Ebola and Marburg Viruses Seroprevalence in Blood Donors in the Republic of Congo, PLOS Neglected Tropical Diseases, vol.2, issue.Suppl 3, p.3833, 2015. ,
DOI : 10.1371/journal.pntd.0003833.s002
URL : https://hal.archives-ouvertes.fr/hal-01207635
Human asymptomatic Ebola infection and strong inflammatory response, The Lancet, vol.355, issue.9222, pp.2210-2215, 2000. ,
DOI : 10.1016/S0140-6736(00)02405-3
Clinical Illness and Outcomes in Patients with Ebola in Sierra Leone, New England Journal of Medicine, vol.371, issue.22, pp.2092-100, 2014. ,
DOI : 10.1056/NEJMoa1411680
Treatment of Ebola virus disease, Intensive Care Medicine, vol.371, issue.12, pp.115-122, 2015. ,
DOI : 10.1007/s00134-014-3529-8
URL : https://hal.archives-ouvertes.fr/hal-01327168
Caring for Critically Ill Patients with Ebola Virus Disease. Perspectives from West Africa, American Journal of Respiratory and Critical Care Medicine, vol.190, issue.7, pp.733-740, 2014. ,
DOI : 10.1164/rccm.201408-1514CP
The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field, Clinical Infectious Diseases, vol.62, issue.1, 2015. ,
DOI : 10.1093/cid/civ680
URL : https://hal.archives-ouvertes.fr/hal-01213888
Clinical Implications of Antiviral Resistance in Influenza, Viruses, vol.7, issue.9, pp.4929-4973, 2015. ,
DOI : 10.3390/v7092850
Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Research, vol.100, issue.2, pp.446-54, 2013. ,
DOI : 10.1016/j.antiviral.2013.09.015
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Research, vol.105, pp.17-21, 2014. ,
DOI : 10.1016/j.antiviral.2014.02.014
Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model, Antiviral Research, vol.104, pp.153-158, 2014. ,
DOI : 10.1016/j.antiviral.2014.01.012
Ebola virus dynamics in mice treated with favipiravir, Antiviral Research, vol.123, pp.70-77, 2015. ,
DOI : 10.1016/j.antiviral.2015.08.015
URL : https://hal.archives-ouvertes.fr/inserm-01196078
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLOS Medicine, vol.27, issue.1, 2015. ,
DOI : 10.1371/journal.pmed.1001967.s011
URL : https://hal.archives-ouvertes.fr/hal-01327168
Dose regimen of favipiravir for Ebola virus disease, The Lancet Infectious Diseases, vol.15, issue.2, pp.150-151, 2015. ,
DOI : 10.1016/S1473-3099(14)71047-3
Favipiravir for children with Ebola, The Lancet, vol.385, issue.9968, pp.603-607, 2015. ,
DOI : 10.1016/S0140-6736(15)60232-X
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430, Nature, vol.47, issue.7496, pp.402-407, 2014. ,
DOI : 10.1038/nature13027
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp, Nature, vol.27, pp.47-53, 2014. ,
DOI : 10.1086/514305
Structures of protective antibodies reveal sites of vulnerability on Ebola virus, Proc. Natl. Acad. Sci, pp.17182-17189, 2014. ,
DOI : 10.1073/pnas.1414164111
Enhanced potency of a fucosefree monoclonal antibody being developed as an Ebola virus immunoprotectant, Proc. Natl. Acad. Sci, pp.20690-20694, 2011. ,
Medicinal products under development for the treatment of Ebola In: Interim assessment report -22 Available from, Report, vol.12, 2014. ,
Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail, Science Translational Medicine, vol.5, issue.199, 2013. ,
DOI : 10.1126/scitranslmed.3006608
Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques, Proc. Natl. Acad. Sci, pp.18030-18035, 2012. ,
DOI : 10.1073/pnas.1213709109
Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb, Scientific Reports, vol.4, p.3365, 2013. ,
DOI : 10.1038/srep03365
mAbs and Ad-Vectored IFN-?? Therapy Rescue Ebola-Infected Nonhuman Primates When Administered After the Detection of Viremia and Symptoms, Science Translational Medicine, vol.5, issue.207, pp.207-143, 2013. ,
DOI : 10.1126/scitranslmed.3006605
Pharmacology and therapeutic potential of interferons, Pharmacology & Therapeutics, vol.135, issue.1, pp.44-53, 2012. ,
DOI : 10.1016/j.pharmthera.2012.03.006
Mini ReviewHuman Interferons Alpha, Beta and Omega, Growth Factors, vol.22, issue.4, pp.243-51, 2004. ,
DOI : 10.1080/08977190400000833
Interferons: Success in anti-viral immunotherapy, Cytokine & Growth Factor Reviews, vol.25, issue.4, pp.369-76, 2014. ,
DOI : 10.1016/j.cytogfr.2014.07.015
Evasion of Interferon Responses by Ebola and Marburg Viruses, Journal of Interferon & Cytokine Research, vol.29, issue.9, pp.511-531, 2009. ,
DOI : 10.1089/jir.2009.0076
Characterization of host immune responses in Ebola virus infections, Expert Review of Clinical Immunology, vol.10, issue.6, pp.781-90, 2014. ,
DOI : 10.1586/1744666X.2014.908705
Apoptosis Induced In Vitro and In Vivo During Infection by Ebola and Marburg Viruses, Laboratory Investigation, vol.235, issue.2, pp.171-86, 2000. ,
DOI : 10.1126/science.279.5353.1034
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities, The Oncologist, vol.6, issue.1, pp.34-55, 2001. ,
DOI : 10.1634/theoncologist.6-1-34
Pharmacokinetics of Interferon ??-2b in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.35, issue.5, pp.432-437, 1987. ,
DOI : 10.1002/j.1552-4604.1987.tb03044.x
Interferon beta assessment in non-Chinese and Chinese subjects: Pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent, The Journal of Clinical Pharmacology, vol.34, issue.12, pp.1153-61, 2014. ,
DOI : 10.1002/jcph.311
Potent in vitro Activity of the Albumin Fusion Type 1 Interferons (Albumin-Interferon-Alpha and Albumin-Interferon-Beta) against RNA Viral Agents of Bioterrorism and the Severe Acute Respiratory Syndrome (SARS) Virus, Chemotherapy, vol.54, issue.3, pp.176-80, 2008. ,
DOI : 10.1159/000140361
Evaluation of Immune Globulin and Recombinant Interferon?????2b for Treatment of Experimental Ebola Virus Infections, The Journal of Infectious Diseases, vol.179, issue.s1, pp.224-258, 1999. ,
DOI : 10.1086/514310
Interferon-?? Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever, Journal of Infectious Diseases, vol.208, issue.2, pp.310-318, 2013. ,
DOI : 10.1093/infdis/jis921
Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques with Monoclonal Antibodies, Science Translational Medicine, vol.4, issue.138, pp.138-81, 2012. ,
DOI : 10.1126/scitranslmed.3003876
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates, Nature, vol.146, issue.7552, pp.362-367, 2015. ,
DOI : 10.1038/nature14442
The promises and pitfalls of RNA-interference-based therapeutics, Nature, vol.13, issue.7228, pp.426-459, 2009. ,
DOI : 10.1038/nature07758
The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States, Clinical Infectious Diseases, vol.61, issue.4, pp.496-502, 2015. ,
DOI : 10.1093/cid/civ334
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study, The Lancet, vol.375, issue.9729, pp.1896-905, 2010. ,
DOI : 10.1016/S0140-6736(10)60357-1
Tekmira Provides Update on TKM-Ebola-Guinea [Internet] Available from: http://www.sec.gov/Archives, 2015. ,
Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies, Antimicrobial Agents and Chemotherapy, vol.58, issue.11, pp.6639-6686, 2014. ,
DOI : 10.1128/AAC.03442-14
Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections, Viruses, vol.4, issue.12, pp.2806-2836, 2012. ,
DOI : 10.3390/v4112806
Advanced antisense therapies for postexposure protection against lethal filovirus infections, Nature Medicine, vol.251, issue.9, pp.991-995, 2010. ,
DOI : 10.1038/nm.2202
A Single Phosphorodiamidate Morpholino Oligomer Targeting VP24 Protects Rhesus Monkeys against Lethal Ebola Virus Infection, mBio, vol.6, issue.1, pp.2344-2358, 2015. ,
DOI : 10.1128/mBio.02344-14
Anticoagulant repertoire of the hookworm Ancylostoma caninum., Proc. Natl. Acad. Sci, pp.2149-54, 1996. ,
DOI : 10.1073/pnas.93.5.2149
Mechanisms Underlying Coagulation Abnormalities in Ebola Hemorrhagic Fever: Overexpression of Tissue Factor in Primate Monocytes/Macrophages Is a Key Event, The Journal of Infectious Diseases, vol.188, issue.11, pp.1618-1647, 2003. ,
DOI : 10.1086/379724
Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia, Journal of Thrombosis and Haemostasis, vol.169, issue.1, pp.65-70, 2004. ,
DOI : 10.1042/CS20010260
Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man. Dependence on the stoichiometric binding to circulating factor X, Thromb. Haemost, vol.90, pp.803-815, 2003. ,
Recombinant Nematode Anticoagulant Protein c2 in Patients With Non???ST-Segment Elevation Acute Coronary Syndrome, Journal of the American College of Cardiology, vol.49, issue.25, pp.2398-407, 2007. ,
DOI : 10.1016/j.jacc.2007.02.065
Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement, Circulation, vol.104, issue.1, pp.74-82, 2001. ,
DOI : 10.1161/hc2601.091386
Inhibition of the tissue factor pathway of coagulation by recombinant nematode anticoagulant protein c2 during elective coronary stent implantation, Neth. Heart J, vol.12, pp.48-54, 2004. ,
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys, The Lancet, vol.362, issue.9400, pp.1953-1961, 2003. ,
DOI : 10.1016/S0140-6736(03)15012-X
The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients, Advanced Drug Delivery Reviews, vol.77, pp.12-21, 2014. ,
DOI : 10.1016/j.addr.2014.05.007
Drug absorption, distribution, metabolism and excretion considerations in critically ill adults, Expert Opinion on Drug Metabolism & Toxicology, vol.47, issue.3, pp.1067-84, 2013. ,
DOI : 10.2165/11636220-000000000-00000
Nonhuman primates as models for the discovery and development of ebolavirus therapeutics, Expert Opinion on Drug Discovery, vol.11, issue.3, pp.233-50, 2011. ,
DOI : 10.1086/514321
An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease -Full Text View -ClinicalTrials.gov [Internet] Available from: https://clinicaltrials, p.1, 2015. ,
Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates, Open Forum Infectious Diseases, vol.2, issue.suppl_1, 2015. ,
DOI : 10.1093/ofid/ofv130.02
Multiple Cationic Amphiphiles Induce a Niemann-Pick C Phenotype and Inhibit Ebola Virus Entry and Infection, PLoS ONE, vol.11, issue.2, p.56265, 2013. ,
DOI : 10.1371/journal.pone.0056265.s002
The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry, Journal of Antimicrobial Chemotherapy, vol.69, issue.8, pp.2123-2154, 2014. ,
DOI : 10.1093/jac/dku091
Identification and Targeting of an Interaction between a Tyrosine Motif within Hepatitis C Virus Core Protein and AP2M1 Essential for Viral Assembly, PLoS Pathogens, vol.8, issue.8, p.1002845, 2012. ,
DOI : 10.1371/journal.ppat.1002845.s001
Identification of a Small-Molecule Entry Inhibitor for Filoviruses, Journal of Virology, vol.85, issue.7, pp.3106-3125, 2011. ,
DOI : 10.1128/JVI.01456-10
A broad-spectrum antiviral targeting entry of enveloped viruses, Proc. Natl. Acad. Sci, pp.3157-62, 2010. ,
DOI : 10.1073/pnas.0909587107
Small molecule inhibitors reveal Niemann???Pick C1 is essential for Ebola virus infection, Nature, vol.30, issue.7364, pp.344-352, 2011. ,
DOI : 10.1038/nature10380
Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection, Antimicrobial Agents and Chemotherapy, vol.54, issue.5, pp.2152-2161, 2010. ,
DOI : 10.1128/AAC.01315-09
FGI-104: A Broad-Spectrum Small Molecule Inhibitor of Viral Infection, Antiviral Research, vol.82, issue.2, pp.87-98, 2009. ,
DOI : 10.1016/j.antiviral.2009.02.082
Development of a broad-spectrum antiviral with activity against Ebola virus, Antiviral Research, vol.83, issue.3, pp.245-51, 2009. ,
DOI : 10.1016/j.antiviral.2009.06.001
HCV Kinetic Models and Their Implications in Drug Development, CPT: Pharmacometrics & Systems Pharmacology, vol.50, issue.4, pp.231-273, 2015. ,
DOI : 10.1002/psp4.28
Viral kinetic modeling: state of the art, Journal of Pharmacokinetics and Pharmacodynamics, vol.5, issue.11, pp.431-474, 2014. ,
DOI : 10.1007/s10928-014-9363-3
Assessment of the Risk of Ebola Virus Transmission from Bodily Fluids and Fomites, The Journal of Infectious Diseases, vol.196, issue.s2, pp.142-149, 2007. ,
DOI : 10.1086/520545
Persistence of Ebola Virus in Ocular Fluid during Convalescence, New England Journal of Medicine, vol.372, issue.25, pp.2423-2430, 2015. ,
DOI : 10.1056/NEJMoa1500306
Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases, The Lancet Infectious Diseases, vol.15, issue.3, pp.356-365, 2015. ,
DOI : 10.1016/S1473-3099(14)71071-0
Ebola Virus Infection: Overview and Update on Prevention and Treatment, Infectious Diseases and Therapy, vol.211, issue.4, 2015. ,
DOI : 10.1007/s40121-015-0079-5
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial, The Lancet, vol.386, issue.9996, pp.857-66, 2015. ,
DOI : 10.1016/S0140-6736(15)61117-5